Eagle Pharmaceuticals (NASDAQ:EGRX) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research note issued to investors on Thursday morning. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Price Performance

Shares of NASDAQ:EGRX opened at $0.65 on Thursday. Eagle Pharmaceuticals has a 12 month low of $0.00 and a 12 month high of $6.81. The company’s 50-day moving average price is $0.68 and its two-hundred day moving average price is $2.55.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of EGRX. Mackenzie Financial Corp bought a new position in Eagle Pharmaceuticals in the second quarter valued at about $60,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Eagle Pharmaceuticals in the 2nd quarter worth $65,000. Fidelis Capital Partners LLC bought a new stake in Eagle Pharmaceuticals in the second quarter valued at about $71,000. Vanguard Personalized Indexing Management LLC bought a new position in Eagle Pharmaceuticals during the second quarter worth about $76,000. Finally, RBF Capital LLC grew its position in shares of Eagle Pharmaceuticals by 11.7% during the 3rd quarter. RBF Capital LLC now owns 143,078 shares of the specialty pharmaceutical company’s stock worth $534,000 after buying an additional 14,991 shares during the period. Institutional investors and hedge funds own 85.36% of the company’s stock.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.